Lawrence S Kirschner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/564912/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>PRKAR1A</i> deficiency impedes hypertrophy and reduces heart size. Physiological Reports, 2020, 8, e14405.	1.7	8
2	Response to Letter to the Editor: "Predictors of Postoperative Diabetes Insipidus Following Endoscopic Resection of Pituitary Adenomas― Journal of the Endocrine Society, 2019, 3, 1459-1460.	0.2	0
3	PKA Activates AMPK Through LKB1 Signaling in Follicular Thyroid Cancer. Frontiers in Endocrinology, 2019, 10, 769.	3.5	23
4	Metastatic Adrenocortical Carcinoma: a Single Institutional Experience. Hormones and Cancer, 2019, 10, 161-167.	4.9	13
5	Elevated aggressive behavior in male mice with thyroid-specific Prkar1a and global Epac1 gene deletion. Hormones and Behavior, 2018, 98, 121-129.	2.1	1
6	Alterations in Sod2-Induced Oxidative Stress Affect Endocrine Cancer Progression. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4135-4145.	3.6	13
7	Predictors of Postoperative Diabetes Insipidus Following Endoscopic Resection of Pituitary Adenomas. Journal of the Endocrine Society, 2018, 2, 1010-1019.	0.2	55
8	Deletion of <i>Rap1b</i> , but not <i>Rap1a</i> or <i>Epac1</i> , Reduces Protein Kinase A–Mediated Thyroid Cancer. Thyroid, 2018, 28, 1153-1161.	4.5	14
9	Sdhd ablation promotes thyroid tumorigenesis by inducing a stem-like phenotype. Endocrine-Related Cancer, 2017, 24, 579-591.	3.1	3
10	Automated MicroSPECT/MicroCT Image Analysis of the Mouse Thyroid Gland. Thyroid, 2017, 27, 1433-1440.	4.5	1
11	Biological Evaluation of a Fluorescent-Imaging Agent for Medullary Thyroid Cancer in an Orthotopic Model. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3268-3277.	3.6	3
12	Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response. Oncotarget, 2017, 8, 104046-104056.	1.8	35
13	Novel targeted therapies in adrenocortical carcinoma. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 233-241.	2.3	13
14	Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters. Thyroid, 2016, 26, 1276-1284.	4.5	32
15	5th International ACC Symposium: The New Genetics of Benign Adrenocortical Neoplasia: Hyperplasias, Adenomas, and Their Implications for Progression into Cancer. Hormones and Cancer, 2016, 7, 9-16.	4.9	6
16	Mouse models of thyroid cancer: A 2015 update. Molecular and Cellular Endocrinology, 2016, 421, 18-27.	3.2	24
17	Inhibition of IGF-1R in adrenocortical carcinoma. Lancet Oncology, The, 2015, 16, 356-357.	10.7	4
18	Knockdown of PRKAR1A, the Gene Responsible for Carney Complex, Interferes With Differentiation in Osteoblastic Cells. Molecular Endocrinology, 2014, 28, 295-307.	3.7	19

#	Article	IF	CITATIONS
19	A unified cause for adrenal Cushing's syndrome. Science, 2014, 344, 804-805.	12.6	12
20	Follicular Thyroid Cancers Demonstrate Dual Activation of PKA and mTOR as Modeled by Thyroid-Specific Deletion of Prkar1a and Pten in Mice. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E804-E812.	3.6	31
21	Protein Kinase A Activation Enhances β-Catenin Transcriptional Activity through Nuclear Localization to PML Bodies. PLoS ONE, 2014, 9, e109523.	2.5	29
22	Gaining Traction in the Treatment of Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 45-47.	3.6	0
23	Thyroid-specific ablation of the Carney complex gene, PRKAR1A, results in hyperthyroidism and follicular thyroid cancer. Endocrine-Related Cancer, 2012, 19, 435-446.	3.1	33
24	The next generation of therapies for adrenocortical cancers. Trends in Endocrinology and Metabolism, 2012, 23, 343-350.	7.1	23
25	Targeted Therapies for Adrenocortical Carcinoma: IGF and Beyond. Hormones and Cancer, 2011, 2, 385-392.	4.9	20
26	Differential Role of PKA Catalytic Subunits in Mediating Phenotypes Caused by Knockout of the Carney Complex Gene Prkar1a. Molecular Endocrinology, 2011, 25, 1786-1793.	3.7	24
27	Alternate protein kinase A activity identifies a unique population of stromal cells in adult bone. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8683-8688.	7.1	42
28	Cushing's Syndrome and Fetal Features Resurgence in Adrenal Cortex–Specific Prkar1a Knockout Mice. PLoS Genetics, 2010, 6, e1000980.	3.5	95
29	Neural Crest-Specific Loss of Prkar1a Causes Perinatal Lethality Resulting from Defects in Intramembranous Ossification. Molecular Endocrinology, 2010, 24, 1559-1568.	3.7	25
30	PRKAR1A and the evolution of pituitary tumors. Molecular and Cellular Endocrinology, 2010, 326, 3-7.	3.2	39
31	Mouse models of endocrine tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 451-460.	4.7	9
32	Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. Journal of Clinical Investigation, 2010, 120, 3310-3325.	8.2	89
33	Mutations in Regulatory Subunit Type 1A of Cyclic Adenosine 5′-Monophosphate-Dependent Protein Kinase (<i>PRKAR1A</i>): Phenotype Analysis in 353 Patients and 80 Different Genotypes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2085-2091.	3.6	399
34	Mouse models of altered protein kinase A signaling. Endocrine-Related Cancer, 2009, 16, 773-793.	3.1	61
35	The Carney complex Gene PRKAR1A Plays an Essential Role in Cardiac Development and Myxomagenesis. Trends in Cardiovascular Medicine, 2009, 19, 44-49	4.9	19
36	Regulation of actin function by protein kinase Aâ€mediated phosphorylation of Limk1. EMBO Reports, 2009. 10. 599-605.	4.5	67

#	Article	IF	CITATIONS
37	New Strategies for the Treatment of Adrenocortical Carcinoma. , 2009, , 493-513.		Ο
38	Development of a pituitaryâ€specific cre line targeted to the Pitâ€l lineage. Genesis, 2008, 46, 37-42.	1.6	14
39	Tissue-Specific Ablation of Prkar1a Causes Schwannomas by Suppressing Neurofibromatosis Protein Production. Neoplasia, 2008, 10, 1213-IN9.	5.3	31
40	Targeted Deletion of <i>Prkar1a</i> Reveals a Role for Protein Kinase A in Mesenchymal-to-Epithelial Transition. Cancer Research, 2008, 68, 2671-2677.	0.9	34
41	Heart-Specific Ablation of <i>Prkar1a</i> Causes Failure of Heart Development and Myxomagenesis. Circulation, 2008, 117, 1414-1422.	1.6	49
42	Pituitary-Specific Knockout of the Carney Complex Gene Prkar1a Leads to Pituitary Tumorigenesis. Molecular Endocrinology, 2008, 22, 380-387.	3.7	73
43	Mutation of Prkar1a Causes Osteoblast Neoplasia Driven by Dysregulation of Protein Kinase A. Molecular Endocrinology, 2008, 22, 430-440.	3.7	31
44	A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in in in individuals with adrenocortical hyperplasia. Nature Genetics, 2006, 38, 794-800.	21.4	316
45	Paradigms for Adrenal Cancer: Think Globally, Act Locally. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4250-4252.	3.6	7
46	Emerging Treatment Strategies for Adrenocortical Carcinoma: A New Hope. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 14-21.	3.6	95
47	Disruption of Protein Kinase A Regulation Causes Immortalization and Dysregulation of D-Type Cyclins. Cancer Research, 2005, 65, 10307-10315.	0.9	65
48	A Mouse Model for the Carney Complex Tumor Syndrome Develops Neoplasia in Cyclic AMP–Responsive Tissues. Cancer Research, 2005, 65, 4506-4514.	0.9	166
49	Down-Regulation of Regulatory Subunit Type 1A of Protein Kinase A Leads to Endocrine and Other Tumors. Cancer Research, 2004, 64, 8811-8815.	0.9	91
50	Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene, 2004, 23, 1575-1585.	5.9	122
51	PROTEIN KINASE A AND TUMORIGENICITY: THE EXAMPLE OF MICRONODULAR ADRENOCORTICAL HYPERPLASIA AND CARNEY COMPLEX. Endocrine Research, 2002, 28, 749-750.	1.2	0
52	Genetic analysis of Carney complex: current understanding and future questions. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 244-249.	0.6	4
53	Molecular Analysis of the Cyclic AMP-Dependent Protein Kinase A (PKA) Regulatory Subunit 1A (PRKAR1A) Gene in Patients with Carney Complex and Primary Pigmented Nodular Adrenocortical Disease (PPNAD) Reveals Novel Mutations and Clues For Pathophysiology: Augmented PKA Signaling is Associated with Adrenal Tumorigenesis in PPNAD. American Journal of Human Genetics, 2002, 71,	6.2	173
54	1433-1442. Adrenal disease in childhood: caught at an awkward age. Trends in Endocrinology and Metabolism, 2002, 13, 270-271.	7.1	0

#	Article	IF	CITATIONS
55	Regulatory subunit type lâ€Î± of protein kinase A (<i>PRKAR1A</i>): A tumorâ€suppressor gene for sporadic thyroid cancer. Genes Chromosomes and Cancer, 2002, 35, 182-192.	2.8	83
56	Sequence analysis of the <i>PRKAR1A</i> gene in sporadic somatotroph and other pituitary tumours. Clinical Endocrinology, 2002, 57, 443-448.	2.4	72
57	Signaling Pathways in Adrenocortical Cancer. Annals of the New York Academy of Sciences, 2002, 968, 222-239.	3.8	51
58	Clinical and Molecular Features of the Carney Complex: Diagnostic Criteria and Recommendations for Patient Evaluation. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4041-4046.	3.6	674
59	Clinical and Molecular Features of the Carney Complex: Diagnostic Criteria and Recommendations for Patient Evaluation. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4041-4046.	3.6	158
60	Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nature Genetics, 2000, 26, 89-92.	21.4	1,091
61	Ovarian Lesions in Carney Complex: Clinical Genetics and Possible Predisposition to Malignancy. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4359-4366.	3.6	76
62	Genetic and Histologic Studies of Somatomammotropic Pituitary Tumors in Patients with the "Complex of Spotty Skin Pigmentation, Myxomas, Endocrine Overactivity and Schwannomas―(Carney) Tj ETG	2 a,0 00rg	gBB6Overloc
63	Neurosurgical implications of Carney complex. Journal of Neurosurgery, 2000, 92, 413-418.	1.6	87
64	Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Human Molecular Genetics, 2000, 9, 3037-3046.	2.9	366
65	Structure of the Human Ubiquitin Fusion Gene Uba80 (RPS27a) and One of Its Pseudogenes. Biochemical and Biophysical Research Communications, 2000, 270, 1106-1110.	2.1	28
66	Ovarian Lesions in Carney Complex: Clinical Genetics and Possible Predisposition to Malignancy. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4359-4366.	3.6	10
67	Paradoxical Response to Dexamethasone in the Diagnosis of Primary Pigmented Nodular Adrenocortical Disease. Annals of Internal Medicine, 1999, 131, 585.	3.9	210
68	Synaptophysin Immunoreactivity in Primary Pigmented Nodular Adrenocortical Disease: Neuroendocrine Properties of Tumors Associated with Carney Complex. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1122-1128.	3.6	55
69	Adipose S14 mRNA is Abnormally Regulated in Obese Subjects. Thyroid, 1999, 9, 143-148.	4.5	16
70	Radiation Hybrid Mapping of Chromosomal Region 2p15–p16: Integration of Expressed and Polymorphic Sequences Maps at the Carney Complex (CNC) and Doyne Honeycomb Retinal Dystrophy (DHRD) Loci. Genomics, 1999, 56, 344-349.	2.9	23
71	Genomic Mapping of Chromosomal Region 2p15–p21 (D2S378–D2S391): Integration of Genemap'98 within a Framework of Yeast and Bacterial Artificial Chromosomes. Genomics, 1999, 62, 21-33.	2.9	28
72	Synaptophysin Immunoreactivity in Primary Pigmented Nodular Adrenocortical Disease: Neuroendocrine Properties of Tumors Associated with Carney Complex. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1122-1128.	3.6	11

#	Article	IF	CITATIONS
73	Carney complex: Diagnosis and management of the complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas. , 1998, 80, 183-185.		68
74	characterization of the adrenal gland pathology of carney complex, and molecular genetics of the disease Endocrine Research, 1998, 24, 863-864.	1.2	12
75	Identification of a Novel Genetic Locus for Familial Cardiac Myxomas and Carney Complex. Circulation, 1998, 98, 2560-2566.	1.6	209
76	Management of a Giant Fluid-filled Bulla by Closed-Chest Thoracostomy Tube Drainage. Chest, 1997, 111, 1772-1774.	0.8	11